-transparent.png){kind=logo}
A group of 11 menopausal women receiving 1.25 mg. of conjugated estrogens daily had coagulation tests to determine the development of hypercoagulability after taking 5 and 21 tablets. There was no essential change in thrombin generation or fibrinolytic activity as measured by euglobin lysis time. There was a shift toward hypercoagulability in all three parameters of the thrombelastograms. The decrease of the antithrombin III activity was not as pronounced following the administration of conjugated estrogens as had been the change associated with oral contraceptives. Fibrin monomers were observed in some women during the first week of Premarin therapy.
Related Publications
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
November 1995,
Deutsche medizinische Wochenschrift (1946),
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
March 2014,
Hospital pharmacy,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
October 1990,
American pharmacy,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
November 2018,
Postgraduate medicine,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
July 1990,
American pharmacy,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
September 1966,
Munchener medizinische Wochenschrift (1950),
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
December 1999,
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
November 1986,
American journal of epidemiology,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
December 1999,
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
E von Kaulla, and
W Droegemueller, and
K N von Kaulla
February 2009,
The Medical letter on drugs and therapeutics,
